TG Therapeutics Stock Forecast, Price & News

+0.73 (+2.44 %)
(As of 09/16/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume1.10 million shs
Average Volume1.47 million shs
Market Capitalization$4.33 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive TGTX News and Ratings via Email

Sign-up to receive the latest news and ratings for TG Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

TG Therapeutics logo

About TG Therapeutics

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

2.30 out of 5 stars

Medical Sector

253rd out of 1,352 stocks

Pharmaceutical Preparations Industry

120th out of 665 stocks

Analyst Opinion: 3.4Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

TG Therapeutics (NASDAQ:TGTX) Frequently Asked Questions

Is TG Therapeutics a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for TG Therapeutics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TG Therapeutics stock.
View analyst ratings for TG Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than TG Therapeutics?

Wall Street analysts have given TG Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but TG Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting TG Therapeutics?

TG Therapeutics saw a increase in short interest during the month of August. As of August 13th, there was short interest totaling 12,820,000 shares, an increase of 12.2% from the July 29th total of 11,430,000 shares. Based on an average trading volume of 1,400,000 shares, the days-to-cover ratio is currently 9.2 days. Approximately 9.7% of the shares of the stock are sold short.
View TG Therapeutics' Short Interest

When is TG Therapeutics' next earnings date?

TG Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, November 8th 2021.
View our earnings forecast for TG Therapeutics

How were TG Therapeutics' earnings last quarter?

TG Therapeutics, Inc. (NASDAQ:TGTX) announced its quarterly earnings data on Sunday, August, 1st. The biopharmaceutical company reported ($0.59) earnings per share for the quarter, missing analysts' consensus estimates of ($0.48) by $0.11. TG Therapeutics had a negative trailing twelve-month return on equity of 90.75% and a negative net margin of 14,271.13%.
View TG Therapeutics' earnings history

How has TG Therapeutics' stock been impacted by Coronavirus?

TG Therapeutics' stock was trading at $10.01 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, TGTX shares have increased by 206.0% and is now trading at $30.63.
View which stocks have been most impacted by COVID-19

What price target have analysts set for TGTX?

4 equities research analysts have issued 1-year price objectives for TG Therapeutics' stock. Their forecasts range from $48.00 to $95.00. On average, they expect TG Therapeutics' share price to reach $69.25 in the next twelve months. This suggests a possible upside of 126.1% from the stock's current price.
View analysts' price targets for TG Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are TG Therapeutics' key executives?

TG Therapeutics' management team includes the following people:
  • Michael Sean Weiss, Chairman, President & Chief Executive Officer
  • Sean A. Power, Chief Financial Officer, Secretary & Treasurer
  • Owen A. O'Connor, Chief Scientific Officer
  • Adam Waldman, Chief Commercial Officer
  • Jenna A. Bosco, Senior Vice President-Corporate Communications

Who are some of TG Therapeutics' key competitors?

What other stocks do shareholders of TG Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TG Therapeutics investors own include Novavax (NVAX), AK Steel (AKS), Micron Technology (MU), Cara Therapeutics (CARA), Gilead Sciences (GILD), UrtheCast (UR), Verastem (VSTM), BioDelivery Sciences International (BDSI), Sorrento Therapeutics (SRNE) and Corbus Pharmaceuticals (CRBP).

What is TG Therapeutics' stock symbol?

TG Therapeutics trades on the NASDAQ under the ticker symbol "TGTX."

Who are TG Therapeutics' major shareholders?

TG Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include FMR LLC (13.20%), Vanguard Group Inc. (8.29%), BlackRock Inc. (5.90%), State Street Corp (2.55%), RA Capital Management L.P. (2.36%) and Lord Abbett & CO. LLC (2.00%). Company insiders that own TG Therapeutics stock include Ra Capital Management, LP, William James Kennedy and Yann Echelard.
View institutional ownership trends for TG Therapeutics

Which institutional investors are selling TG Therapeutics stock?

TGTX stock was sold by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, RA Capital Management L.P., BlackRock Inc., Woodline Partners LP, Goldman Sachs Group Inc., Bank of America Corp DE, Credit Suisse AG, and Emerald Advisers LLC.
View insider buying and selling activity for TG Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying TG Therapeutics stock?

TGTX stock was purchased by a variety of institutional investors in the last quarter, including Westfield Capital Management Co. LP, FMR LLC, Vanguard Group Inc., Fisher Asset Management LLC, JPMorgan Chase & Co., State Street Corp, Price T Rowe Associates Inc. MD, and Morgan Stanley.
View insider buying and selling activity for TG Therapeutics
or or view top insider-buying stocks.

How do I buy shares of TG Therapeutics?

Shares of TGTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is TG Therapeutics' stock price today?

One share of TGTX stock can currently be purchased for approximately $30.63.

How much money does TG Therapeutics make?

TG Therapeutics has a market capitalization of $4.33 billion and generates $150,000.00 in revenue each year. The biopharmaceutical company earns $-279,380,000.00 in net income (profit) each year or ($2.42) on an earnings per share basis.

How many employees does TG Therapeutics have?

TG Therapeutics employs 272 workers across the globe.

What is TG Therapeutics' official website?

The official website for TG Therapeutics is

Where are TG Therapeutics' headquarters?

TG Therapeutics is headquartered at 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014.

How can I contact TG Therapeutics?

TG Therapeutics' mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The biopharmaceutical company can be reached via phone at (212) 554-4484 or via email at [email protected]

This page was last updated on 9/16/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.